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Editorial
IMPORTANCE Detailed information about the association of COVID-19 with outcomes in
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pregnant individuals compared with not-infected pregnant individuals is much needed.
OBJECTIVE To evaluate the risks associated with COVID-19 in pregnancy on maternal and

neonatal outcomes compared with not-infected, concomitant pregnant individuals.
DESIGN, SETTING, AND PARTICIPANTS In this cohort study that took place from March to
October 2020, involving 43 institutions in 18 countries, 2 unmatched, consecutive,
not-infected women were concomitantly enrolled immediately after each infected woman
was identified, at any stage of pregnancy or delivery, and at the same level of care to minimize
bias. Women and neonates were followed up until hospital discharge.
EXPOSURES COVID-19 in pregnancy determined by laboratory confirmation of COVID-19
and/or radiological pulmonary findings or 2 or more predefined COVID-19 symptoms.
MAIN OUTCOMES AND MEASURES The primary outcome measures were indices of (maternal
and severe neonatal/perinatal) morbidity and mortality; the individual components of these
indices were secondary outcomes. Models for these outcomes were adjusted for country,
month entering study, maternal age, and history of morbidity.
RESULTS A total of 706 pregnant women with COVID-19 diagnosis and 1424 pregnant women
without COVID-19 diagnosis were enrolled, all with broadly similar demographic
characteristics (mean [SD] age, 30.2 [6.1] years). Overweight early in pregnancy occurred in
323 women (48.6%) with COVID-19 diagnosis and 554 women (40.2%) without. Women
with COVID-19 diagnosis were at higher risk for preeclampsia/eclampsia (relative risk [RR],
1.76; 95% CI, 1.27-2.43), severe infections (RR, 3.38; 95% CI, 1.63-7.01), intensive care unit
admission (RR, 5.04; 95% CI, 3.13-8.10), maternal mortality (RR, 22.3; 95% CI, 2.88-172),
preterm birth (RR, 1.59; 95% CI, 1.30-1.94), medically indicated preterm birth (RR, 1.97; 95%
CI, 1.56-2.51), severe neonatal morbidity index (RR, 2.66; 95% CI, 1.69-4.18), and severe
perinatal morbidity and mortality index (RR, 2.14; 95% CI, 1.66-2.75). Fever and shortness of
breath for any duration was associated with increased risk of severe maternal complications
(RR, 2.56; 95% CI, 1.92-3.40) and neonatal complications (RR, 4.97; 95% CI, 2.11-11.69).
Asymptomatic women with COVID-19 diagnosis remained at higher risk only for maternal
morbidity (RR, 1.24; 95% CI, 1.00-1.54) and preeclampsia (RR, 1.63; 95% CI, 1.01-2.63). Among
women who tested positive (98.1% by real-time polymerase chain reaction), 54 (13%) of their
neonates tested positive. Cesarean delivery (RR, 2.15; 95% CI, 1.18-3.91) but not breastfeeding
(RR, 1.10; 95% CI, 0.66-1.85) was associated with increased risk for neonatal test positivity.
CONCLUSIONS AND RELEVANCE In this multinational cohort study, COVID-19 in pregnancy was
associated with consistent and substantial increases in severe maternal morbidity and
mortality and neonatal complications when pregnant women with and without COVID-19
diagnosis were compared. The findings should alert pregnant individuals and clinicians to
implement strictly all the recommended COVID-19 preventive measures.
JAMA Pediatr. doi:10.1001/jamapediatrics.2021.1050
Published online April 22, 2021.
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t the outset of the COVID-19 pandemic, the precise extent of the risks in pregnancy was uncertain, which was
affecting pregnant individuals’ mental health.1,2 The
lack of clarity arose because, in an early systematic review,3
only 4 studies that involved small numbers compared outcomes between pregnant women w ith and w ithout
COVID-19.4-7 The question is relevant because of the known
deleterious effects of other coronavirus infections in pregnancy (eg, severe acute respiratory syndrome and Middle East
respiratory syndrome).8 Therefore, the INTERGROWTH-21st
Consortium conducted a prospective, longitudinal, observational study (INTERCOVID), involving 43 hospitals in 18 countries, to assess the association between COVID-19 and maternal and neonatal outcomes in pregnant women with COVID-19
diagnosis, compared with concomitantly enrolled pregnant
women without COVID-19 diagnosis.

Methods
Study Design
The Oxford Tropical Research Ethics Committee and all local
ethics committees approved the study, which did not interfere with clinical management. Informed consent (oral or written) was obtained from study participants according to local
requirements, except when a waiver/exemption of such consent was granted by a local committee. We adhered to the Declaration of Helsinki9 and Good Clinical Practice guidelines. The
study protocol, including the laboratory tests used, has been
previously published.10
For 8 months from March 2, 2020, we enrolled women 18
years or older at any stage of pregnancy or delivery with the
diagnosis of COVID-19 during the present pregnancy based on
laboratory confirmation of COVID-19 and/or radiologic pulmonary findings suggestive of COVID-1911 or 2 or more predefined COVID-19 symptoms. A range of different real-time
polymerase chain reaction and antibody tests were used at participating institutions (eBox in the Supplement). Two immediately concomitant pregnant women 18 years or older without any of those diagnostic criteria were enrolled per woman
with COVID-19 diagnosis to create an unbiased sample of all
pregnant women without COVID-19 diagnosis in these institutions. Women were enrolled from 43 institutions in 18 countries (Argentina, Brazil, Egypt, France, Ghana, India, Indonesia, Italy, Japan, Mexico, Nigeria, North Macedonia, Pakistan,
Russia, Spain, Switzerland, UK, and the US). Data on race were
not collected.
When a woman with a COVID-19 diagnosis was identified
antenatally, 2 women without COVID-19 diagnosis of similar
gestational age (±2 weeks) receiving standard antenatal care
were enrolled that day. If not possible or if those women without COVID-19 diagnosis were lost to follow-up, we enrolled 2
women without COVID-19 diagnosis who delivered immediately after the woman with COVID-19 diagnosis. The same selection strategy was used when a woman with COVID-19 diagnosis was identified at hospital admission and delivery was
likely during that admission. If a woman without COVID-19 diagnosis declined participation, the next woman was
E2

Key Points
Question To what extent does COVID-19 in pregnancy alter the
risks of adverse maternal and neonatal outcomes compared with
pregnant individuals without COVID-19?
Findings In this multinational cohort study of 2130 pregnant
women in 18 countries, women with COVID-19 diagnosis were at
increased risk of a composite maternal morbidity and mortality
index. Newborns of women with COVID-19 diagnosis had
significantly higher severe neonatal morbidity index and severe
perinatal morbidity and mortality index compared with newborns
of women without COVID-19 diagnosis.
Meaning This study indicates a consistent association between
pregnant individuals with COVID-19 diagnosis and higher rates of
adverse outcomes, including maternal mortality, preeclampsia,
and preterm birth compared with pregnant individuals without
COVID-19 diagnosis.

approached until 2 women without COVID-19 diagnosis were
enrolled per woman with COVID-19 diagnosis. We sought confirmation from a biweekly random 10% sample that the 2
women without COVID-19 diagnosis were appropriately chosen; we excluded 5 women who had a COVID-19 diagnosis and
the corresponding 10 women without a COVID-19 diagnosis,
without such confirmation. Live and stillborn singleton and
multiple pregnancies were included, including those with congenital anomalies. However, in keeping with reporting requirements during the pandemic,12 we excluded women/neonates
from the final analysis if their data were already published in
any comparative study with women without COVID-19
diagnosis.5,13-23

Outcomes
The primary outcomes24 were 3 unweighted indices: (1) maternal morbidity and mortality index including at least 1 of the
following pregnancy-related morbidities: third-trimester vaginal bleeding, pregnancy-induced hypertension, preeclampsia/
eclampsia/hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, preterm labor, infections
requiring antibiotics, or any other pregnancy-related conditions requiring treatment or referral; maternal admission to the
intensive care unit (ICU); referral to a higher level of care; or
death; (2) severe neonatal morbidity index (SNMI) including
at least 3 of the following severe complications: bronchopulmonary dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring transfusion, patent ductus arteriosus requiring treatment or surgery, intraventricular hemorrhage, and
necrotizing enterocolitis or retinopathy of prematurity diagnosed before hospital discharge; and (3) severe perinatal morbidity and mortality index (SPMMI) including fetal death, at
least 1 of the severe neonatal conditions listed above, admission to the neonatal ICU (NICU) for 7 days or longer, or neonatal death before hospital discharge. Secondary outcomes
were each individual component of the indices described above
considered as separate conditions.
Gestational age estimation was based on ultrasonography measurement of fetal crown-rump length (<14 weeks’ gestation) against the international INTERGROWTH-21st
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standards25 or, if early ultrasonography dating was not carried out, the best obstetric estimate was used based on all clinical and ultrasonography data available at the time of delivery. Newborn weight, length, and head circumference at birth
were assessed against the international INTERGROWTH-21st
standards.26

Data Management and Statistical Analysis
We used a centrally coordinated data management system
developed for the IN TERGROWTH-21st P rojec t
(MedSciNet).27 Associations between being diagnosed as
having COVID-19 and morbidity/mortality indices expressed
as binary outcomes were assessed using Poisson models
w ith a log link function and robust standard errors
expressed as relative risk (RR) and 95% CI. Associations
with number of days in ICU were assessed using negative
binomial models with robust standard errors (expressed as
an incidence rate ratio and 95% CI). We set statistical significance at P < .05. Models for our primary outcomes were
adjusted for country, month entering study, maternal age,
and history of maternal morbidity (including diabetes, thyroid, and other endocrine disorders; cardiac disease; hypertension; chronic respiratory disease; kidney disease;
malaria; or tuberculosis). Models with preterm birth as an
outcome were also adjusted for previous preterm birth. We
plotted Kaplan-Meier curves with the percentage of women
remaining pregnant by gestational age to compare the distributions between women with and without COVID-19 diagnosis, according to symptom status. We evaluated women
with COVID-19 diagnosis for the primary and secondary outcomes using the women without COVID-19 diagnosis as the
reference group. We further categorized women with
COVID-19 diagnosis as asymptomatic or symptomatic based
on type and duration of symptoms, as well as according to
past maternal morbidity and normal weight or overweight
to explore effect modification. We assessed the association
of neonates testing positive for SARS-CoV-2 infection. In
separate sensitivity analyses, we adjusted for additional
potential confounders, restricted the definition of women
with COVID-19 diagnosis to mothers with a positive laboratory test result, and excluded twins. We also performed
separate meta-analyses for our primary outcomes of interest using the stratified results to estimate pooled effects and
assess heterogeneity by country.

Results
We enrolled 706 women with COVID-19 diagnosis, of which
656 (92.9%) had laboratory/radiological confirmation and
50 (7.1%) had more than 2 symptoms without laboratory
confirmation. Of those who tested positive, almost exclusively (640 of 652 [98.1%]) by real-time polymerase chain
reaction, 287 (44.0%) were asymptomatic. We also enrolled
1424 women without COVID-19 diagnosis (eFigure in the
Supplement). The groups of women with and without diagnosis had similar demographic characteristics. However,
48.6% (n = 323) of the group with COVID-19 diagnosis had
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overweight early in pregnancy compared with 40.2%
(n = 554) of the group without COVID-19 diagnosis. Women
with COVID-19 diagnosis had a higher rate of recreational
drug use but lower rate of smoking during the index pregnancy, higher rates of previous preterm birth, stillbirth, neonatal death, and preexisting medical conditions (eTable 1 in
the Supplement).
During the index pregnancy, women with a COVID-19 diagnosis had higher rates of pregnancy-induced hypertension
(RR, 1.46; 95% CI, 1.05-2.02), preeclampsia/eclampsia (RR, 1.76;
95% CI, 1.27-2.43), and infections requiring antibiotics
(RR, 3.38; 95% CI, 1.63-7.01), and there was an association with
a greater risk of admission to ICU/high-dependency unit
(RR, 5.04; 95% CI, 3.13-8.10) and referral to a higher level of
care (RR, 6.07; 95% CI, 1.23-30.01). Among all ICU admissions, women with COVID-19 diagnosis stayed 3.73 (95% CI,
2.37-5.86) days longer than women without COVID-19
diagnosis (Table 1).
Eleven women (1.6%) with COVID-19 diagnosis died (maternal mortality ratio, 159/10 000 births). Of these, 4 had severe preeclampsia (1 superimposed on chronic hypertension
and 1 associated with cardiomyopathy); 3 of these 4 women
had respiratory failure that required mechanical ventilation and
the fourth woman died of a pulmonary embolism. Five women
had worsening respiratory failure antenatally, 2 of whom underwent cesarean delivery and, despite intensive respiratory
support, died later. The remaining 2 women developed fever,
cough, and breathlessness within 7 days of an uneventful delivery and died shortly after, despite ICU care. In the group of
women without COVID-19 diagnosis, there was 1 death due to
preexisting liver malignant neoplasm and cirrhosis. Thus,
women with COVID-19 diagnosis were 22 times more likely to
die (RR, 22.3; 95% CI, 2.88-172), although the CIs were wide
owing to the small numbers (Table 1).
Overall, women with COVID-19 diagnosis had a lower
rate of spontaneous initiation of labor but higher cesarean
delivery rate, reflecting the higher rates of pregnancy complications in this group. They also had higher RRs for preterm birth and fetal distress of 1.59 (95% CI, 1.30-1.94) and
1.70 (95% CI, 1.06-2.75), respectively. Overall, 83% of preterm births (n = 130) in women with COVID-19 diagnosis
were medically indicated; hence, the increased risk in this
group (RR, 1.97; 95% CI, 1.56-2.51) (Table 1). The leading
indications for preterm delivery among women with
COVID-19 diagnosis were preeclampsia/eclampsia/HELLP
(31 [24.7%]), small for gestational age (24 [15.5%]), and fetal
distress (17 [13.2%]). The proportions of spontaneous preterm birth were similar. Women with COVID-19 diagnosis
had a higher low birth weight rate (RR, 1.58; 95% CI, 1.291.94). The rates of prelabor rupture of membranes were
similar in both groups (Table 1). Fully adjusting models of
our primary outcomes for all planned variables reduced the
sample size owing to missing data, but affected the results
minimally (eTable 2 in the Supplement).
Women with COVID-19 diagnosis delivered earlier than those
without COVID-19 diagnosis after approximately 30 weeks’ gestation, with the greatest difference less than 37 weeks’ gestation. The Figure illustrates the probability of remaining preg-
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Table 1. Pregnancy Complications, Perinatal Events, and Neonatal Morbidities
Among Women With and Without COVID-19 Diagnosis and Their Newborns
No. (%)
Women with COVID-19
diagnosis (n = 706)
225 (31.9)

Women without
COVID-19 diagnosis
(n = 1424)
296 (20.8)

Relative risk (95% CI)
1.54 (1.33 to 1.78)b

Vaginal bleeding

44 (6.2)

87 (6.1)

1.02 (0.72 to 1.46)

Pregnancy-induced hypertension

58 (8.2)

80 (5.6)

1.46 (1.05 to 2.02)

Preeclampsia/eclampsia/HELLP

59 (8.4)

63 (4.4)

1.76 (1.27 to 2.43)b

Hemoglobin level <10 g/dL at >27 wk gestation

130 (18.4)

228 (16.0)

1.15 (0.91 to 1.45)

Preterm labor

52 (7.4)

88 (6.2)

1.20 (0.86 to 1.68)

Infections requiring antibiotics

25 (3.6)

16 (1.1)

3.38 (1.63 to 7.01)

Admitted to ICU

59 (8.4)

23 (1.6)

5.04 (3.13 to 8.10)

Time in ICU, mean (SD), d

7.3 (7.8)

2.0 (1.7)

3.73 (2.37 to 5.86)c

Referred for higher dependency care

6 (0.9)

1 (0.1)

6.07 (1.23 to 30.01)

Maternal death

11 (1.6)

1 (0.1)

22.26 (2.88 to 172.11)

Fetal distress

87 (12.3)

120 (8.4)

1.70 (1.06 to 2.75)b

Spontaneous initiation of labor

333 (47.2)

793 (55.7)

0.85 (0.77 to 0.93)

Induced labor

157 (22.3)

320 (22.5)

0.99 (0.84 to 1.18)

Cesarean delivery

346 (49.0)

547 (38.4)

1.28 (1.16 to 1.40)b

Prelabor rupture of membranes

114 (16.1)

262 (18.4)

0.87 (0.71 to 1.07)

Gestational age at birth, mean (SD), wk

37.9 (3.3)

38.5 (3.1)

−0.61 (−0.90 to −0.32)d

Preterm birth (<37 wk gestation)

159 (22.5)

194 (13.6)

1.59 (1.30 to 1.94)e

Spontaneous preterm birth

27 (3.8)

66 (4.6)

0.81 (0.52 to 1.27)

Medically indicated preterm birth

133 (18.8)

127 (8.9)

1.97 (1.56 to 2.51)e

Birth weight, mean (SD), kg

2.96 (0.70)

3.07 (0.68)

−0.11 (−0.18 to −0.04)d

Male

353 (50.0)

749 (52.6)

0.95 (0.87 to 1.04)

Female

353 (50.0)

675 (47.6)

1.06 (0.96 to 1.16)

Low birth weight (<2500 g)

145 (20.5)

181 (12.7)

1.58 (1.29 to 1.94)b

Small for gestational age (<10th centile)f

97 (13.7)

181 (12.7)

1.03 (0.81 to 1.31)

Exclusive breastfeeding at discharge

378 (53.5)

953 (66.9)

0.80 (0.74 to 0.87)

Any breastfeeding at discharge

588 (83.3)

1290 (90.6)

0.92 (0.88 to 0.96)

SNMIg

44 (6.2)

33 (2.3)

2.66 (1.69 to 4.18)b

Severe perinatal morbidity and mortality indexh

120 (17.0)

113 (7.9)

2.14 (1.66 to 2.75)b

Characteristic
Maternal morbidity and mortality indexa

Abbreviations: HELLP, hemolysis, elevated liver enzymes, low platelet count;
ICU, intensive care unit; SNMI, severe neonatal morbidity index.

e

Models for preterm birth adjusted for history of preterm birth, country, month
entering study, maternal age, and history of maternal morbidity (including
diabetes, thyroid and other endocrine disorders, cardiac disease,
hypertension, chronic respiratory disease, kidney disease, malaria, or
tuberculosis).

SI conversion factors: To convert hemoglobin to grams per liter, multiply by 10.
a

b

Maternal morbidity and mortality index includes at least 1 of the following
complications during pregnancy: vaginal bleeding, pregnancy-induced
hypertension, preeclampsia, eclampsia, HELLP, preterm labor, infections
requiring antibiotics or maternal death, admission to ICU, or referral for higher
dependency care.
Models adjusted for country, month entering study, maternal age, and history
of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).

c

Incidence rate ratio and 95% CI are reported.

d

β and 95% CI are reported.

nant after 25 weeks’ gestation for those women with COVID-19
diagnosis, stratified into those with and without symptoms.
Using the log-rank test for trend of survivor curves, we observed a significant downwards trend in the gestational age distributions that progressed from women without COVID-19 diagnosis, to asymptomatic women with COVID-19 diagnosis, to
symptomatic women with COVID-19 diagnosis (P < .001 for this
trend) (Figure). In regression models, the gestational age at delivery was 0.6 weeks shorter (95% CI, −0.9 to −0.3) in all women
E4

f

Against the international INTERGROWTH-21st Newborn Size Standards.22

g

SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.

h

Severe perinatal morbidity and mortality index includes any of the morbidities
listed in the SNMI or intrauterine or neonatal death or neonatal ICU stay ⱖ7
days.

with COVID-19 diagnosis and 0.8 weeks shorter (95% CI, −1.2 to
−0.5) in symptomatic women with COVID-19 diagnosis than in
women without COVID-19 diagnosis.
The risk of the SNMI among neonates of women with
COVID-19 diagnosis was significantly higher (RR, 2.66; 95% CI,
1.69-4.18) than in those of women without COVID-19 diagnosis. The risk of the SPMMI was more than twice as high in the
group of women with COVID-19 diagnosis (RR, 2.14; 95% CI,
1.66-2.75) (Table 1).

JAMA Pediatrics Published online April 22, 2021 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Aga Khan University User on 05/31/2021

jamapediatrics.com

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection

Original Investigation Research

Figure. Gestational Age at Delivery Among Women With COVID-19 Diagnosis,
With and Without Symptoms, and Women Without COVID-19 Diagnosis

Individuals remaining pregnant, %

100

80
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40

20

0
20

COVID-19 not diagnosed
COVID-19 diagnosed (asymptomatic)
COVID-19 diagnosed (symptomatic)

25

30

35

40

45

Gestational age at delivery, wk
No. at risk
COVID-19 not diagnosed
COVID-19 diagnosed (asymptomatic)
COVID-19 diagnosed (symptomatic)

1391 1381 1371 1359 1318 1131
284 283 280 276 261 214
407 403 399 382 355 267

A total of 416 neonates born to women with COVID-19 diagnosis were tested for SARS-CoV-2 (57.1% [n = 729] of the total
mother with COVID-19 diagnosis/neonate dyads); 220 (51.5%)
were tested in the first 24 hours after birth and 369 (84.8%) within
the first 48 hours. Of these, 54 (12.9%) tested positive. Among testpositive women with test-positive neonates, the cesarean delivery rate was 72.2% (n = 39) and among test-positive women with
test-negative neonates was 47.9% (n = 173). The rate in women
without COVID-19 diagnosis was 39.4% (n = 568).
In regression models, exploring factors associated with
neonatal SARS-CoV-2 positivity that included gestational age
at delivery, cesarean delivery, NICU stay 7 days or longer, and
exclusive breastfeeding at discharge, only cesarean delivery
was independently associated with the risk of a test-positive
neonate (RR, 2.15; 95% CI, 1.18-3.91). Reassuringly, there was
no association between exclusive breastfeeding and neonatal
test positivity (RR, 1.10; 95% CI, 0.66-1.85).
eTable 3 in the Supplement shows the type, number, and
prevalence of symptoms reported. Overall, the presence of any
symptoms increased the association with adverse outcomes compared with the group of women without COVID-19 diagnosis. Although asymptomatic women with COVID-19 diagnosis had limited risk for most outcomes, there was still an association between
the disease and preeclampsia (RR, 1.63; 95% CI, 1.01-2.63). The
presence of fever and shortness of breath, separately or in combination with any symptom cluster, was markedly associated with
a risk of the 3 summary indices, as well as preterm birth (Table 2).
Having shortness of breath, chest pain, and cough with fever was associated with a substantial increase in the risk for
severe maternal and neonatal conditions and preterm birth.
However, it appears that a longer exposure to symptoms is
needed to see an associated increase in risk for preeclampsia,
eg, 5 to 10 days of respiratory symptoms (RR, 2.43; 95% CI, 1.294.58) (eTable 4 in the Supplement).
Among those with no prepregnancy morbidities and those
without overweight at their first antenatal visit, women with
COVID-19 diagnosis were still at increased risk of these complications compared with women without COVID-19 diagnosis.

435
70
92

11
0
1

There were 1420 women without
COVID-19 diagnosis (dark blue). In the
group of women with COVID-19
diagnosis, 417 women were
symptomatic (light blue) and 288
women were asymptomatic (orange).
There was a significant trend
(P < .001) in shorter gestational age
at delivery going from women
without COVID-19 diagnosis, to
asymptomatic women with COVID-19
diagnosis, to symptomatic women
with COVID-19 diagnosis (log-rank
test for trend of survivor curves). Five
women with missing data were
excluded from the figure.

However, for maternal outcomes, those women with COVID-19
diagnosis with prepregnancy morbidities had the highest risk in
the index pregnancy, suggesting that past morbidities modify
the effect of COVID-19 exposure, especially for preeclampsia/
eclampsia (RR, 3.29; 95% CI, 2.03-5.33) (Table 3). Women who
had overweight at the first antenatal visit and subsequently were
diagnosed with COVID-19 had the highest risk for the maternal
morbidity and mortality index (RR, 1.81; 95% CI, 1.48-2.21), SNMI
(RR, 4.15; 95% CI, 2.15-8.01), and SPMMI and preeclampsia/
eclampsia (RR, 2.62; 95% CI, 1.57-4.36), suggesting that overweight status modifies the effect of COVID-19 exposure (Table 3).
We also compared the risk for severe neonatal complications
in test-positive and test-negative neonates of women with and
without COVID-19 diagnosis, the latter as a reference group. The
risks for the SNMI, SPMMI, and NICU stay 7 days or longer were
higher in the test-negative neonates of women with COVID-19 diagnosis. However, the test-positive neonates of women with
COVID-19 diagnosis had considerably higher risk for the SPMMI
and, as expected, a large increased risk for a NICU stay of 7 days
or longer (Table 4).
In separate sensitivity analyses, adjusting for additional confounders (marital status, overweight, smoking and drug use during pregnancy), restricting mothers with COVID-19 diagnosis to
laboratory-confirmed positive results and excluding twins, we
found that relative risks for COVID-19–associated maternal and
neonatal morbidities were similar to our main results (eTable 2
in the Supplement). Furthermore, we treated each country (all
hospitals in a country pooled) as if they were separate studies in
a meta-analysis. The pooled estimated RRs (95% CI) were practically identical to the unadjusted and adjusted estimations, except for the SNMI, which was increased from the unadjusted RR
of 2.69 (95% CI, 1.72-4.20) to 2.91 (95% CI, 1.76-4.74). As expected,
considering the variability of underlying populations and care systems, we identified some heterogeneity of RR estimates across
countries in the meta-analysis for the maternal morbidity and
mortality index (I2 = 50.0%; P = .02) and SPMMI (I2 = 57.4%; P =
.005), although there was no systematic pattern among the
countries.
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Table 2. Adjusted Associations for Maternal and Perinatal Outcomes
Among Women With and Without COVID-19 Diagnosis According to Symptom Statusa
RR (95% CI)
Symptom

No. (%)

MMMIb

SNMIc

SPMMId

Preterm birthe

Preeclampsia/
eclampsia/HELLP

No diagnosis of COVID-19

1424 (66.9)

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

Asymptomatic

288 (13.5)

1.24 (1.00-1.54)

1.42 (0.65-3.08)

1.08 (0.69-1.69)

0.99 (0.72-1.36)

1.63 (1.01-2.63)

Any symptom

418 (19.6)

1.76 (1.49-2.08)

3.45 (2.14-5.56)

3.09 (2.36-4.04)

2.10 (1.67-2.62)

2.00 (1.34-2.99)

48 (2.3)

1.36 (0.85-2.19)

4.66 (1.93-11.30)

2.79 (1.57-4.95)

2.76 (1.77-4.30)

0.48 (0.07-3.81)

COVID-19

Symptomatic
With diarrhea/vomiting
With fever

199 (9.3)

1.89 (1.54-2.32)

4.34 (2.53-7.43)

3.81 (2.81-5.17)

2.39 (1.82-3.13)

1.82 (1.08-3.06)

With shortness of breath

89 (4.2)

2.46 (1.96-3.08)

3.88 (1.78-8.49)

3.86 (2.62-5.67)

2.88 (2.12-3.89)

2.72 (1.59-4.64)

With fever and shortness
of breath

45 (2.1)

2.56 (1.92-3.40)

4.97 (2.11-11.69)

5.09 (3.30-7.86)

3.40 (2.38-4.86)

2.22 (1.06-4.64)

Abbreviations: HELLP, hemolysis, elevated liver enzymes, low platelet count;
MMMI, maternal morbidity and mortality index; RR, relative risk; SNMI, severe
neonatal morbidity index; SPMMI, severe perinatal morbidity and mortality
index.
a

b

All models adjusted for country, month entering study, maternal age, and
history of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).
MMMI includes at least 1 of the following complications during pregnancy:
vaginal bleeding, pregnancy-induced hypertension, preeclampsia, eclampsia,

HELLP, preterm labor, infections requiring antibiotics or maternal death,
admission to intensive care unit, or referral for higher dependency care.
c

SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.

d

SPMMI includes any of the morbidities listed in the SNMI, intrauterine or
neonatal death, or neonatal intensive care unit stay ⱖ7 days.

e

Models for preterm birth also adjusted for history of preterm birth.

Table 3. Adjusted Associations Between Preexisting Maternal Morbidity or Being Overweight Prepregnancy
and Maternal and Neonatal Outcomes According to COVID-19 Diagnosisa,b
RR (95% CI)
Maternal COVID-19
diagnosis

No. (%)

MMMIc

SNMId

SPMMIe

Preterm birthf

Preeclampsia/
eclampsia/HELLP

No past morbidity

1179 (55.4)

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

Past morbidity

245 (11.5)

1.20 (0.92-1.54)

3.04 (1.48-6.28)

1.48 (0.95-2.29)

1.73 (1.26-2.39)

1.86 (1.11-3.12)

No past morbidity

547 (25.7)

1.57 (1.33-1.85)

4.02 (2.39-6.76)

2.35 (1.76-3.13)

1.76 (1.40-2.22)

1.88 (1.24-2.86)

Past morbidity

159 (7.5)

1.71 (1.33-2.20)

1.88 (0.74-4.73)

2.29 (1.50-3.51)

1.96 (1.41-2.73)

3.29 (2.03-5.33)

Normal weight

823 (40.3)

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

1 [Reference]

Overweight

554 (27.1)

1.01 (0.81-1.24)

1.56 (0.76-3.20)

1.14 (0.78-1.67)

0.78 (0.59-1.05)

1.37 (0.82-2.30)

Normal weight

342 (16.8)

1.28 (1.03-1.58)

2.07 (0.99-4.31)

1.99 (1.38-2.88)

1.42 (1.07-1.90)

1.80 (1.06-3.07)

Overweight

323 (15.8)

1.81 (1.48-2.21)

4.15 (2.15-8.01)

2.44 (1.72-3.48)

1.43 (1.08-1.85)

2.62 (1.57-4.36)

Not diagnosed

Diagnosed

Not diagnosed

Diagnosed

E6

Abbreviations: HELLP, Hemolysis, elevated liver enzymes, low platelet count;
MMMI, maternal morbidity and mortality index; RR, relative risk; SNMI, severe
neonatal morbidity index; SPMMI, severe perinatal morbidity and mortality
index.

c

MMMI includes at least 1 of the following complications during pregnancy:
vaginal bleeding, pregnancy-induced hypertension, preeclampsia, eclampsia,
HELLP, preterm labor, infections requiring antibiotics or maternal death,
admission to intensive care unit, or referral for higher dependency care.

a

All models adjusted for country, month entering study, maternal age, and
history of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).

d

SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.

b

Prepregnancy maternal morbidities included at least 1 of the following:
diabetes, thyroid and other endocrine disorders, cardiac disease,
hypertension, chronic respiratory disease, kidney disease, malaria, or
tuberculosis.

e

SPMMI includes any of the morbidities listed in the SNMI, intrauterine or
neonatal death, or neonatal intensive care unit stay ⱖ7 days.

f

Models for preterm birth also adjusted for history of preterm birth.
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Table 4. Adjusted Associations Between Maternal and Neonatal COVID-19 Diagnosis With Perinatal Morbidity and Mortalitya
RR (95% CI)
Maternal and neonatal COVID-19 diagnosis

No. (%)

SNMIb

SPMMIc

Not-diagnosed mother and neonate

1462 (66.7)

1 [Reference]

1 [Reference]

1 [Reference]

Diagnosed mother but neonate not tested

313 (14.3)

1.40 (0.72-2.70)

1.68 (1.20-2.37)

1.02 (0.60-1.83)

Diagnosed mother but test-negative neonate

362 (16.5)

4.00 (2.29-6.97)

2.31 (1.69-3.17)

3.13 (2.10-4.65)

Diagnosed mother and test-positive neonate

54 (2.5)

4.13 (1.69-10.08)

3.46 (2.13-5.63)

6.03 (3.35-10.86)

Abbreviations: NICU, neonatal intensive care unit; RR, relative risk; SNMI,
severe neonatal morbidity index; SPMMI, severe perinatal morbidity and
mortality index.
a

Models adjusted for country, month entering study, maternal age, and history
of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).

Discussion
We conducted a large-scale, prospective, multinational study
to assess the symptoms and associations between COVID-19
in pregnancy and maternal and neonatal outcomes that included, to our knowledge for the first time, immediately concomitant pregnant women without COVID-19 diagnosis from
the same populations, carefully enrolled to minimize selection bias.
We demonstrated that women with COVID-19 diagnosis,
compared with those without COVID-19 diagnosis, were at substantially increased risk of severe pregnancy complications,
including preeclampsia/eclampsia/HELLP syndrome, ICU admission or referral to higher level of care, and infections requiring antibiotics, as well as preterm birth and low birth
weight. The risk of maternal mortality was 1.6%, ie, 22 times
higher in the group of women with COVID-19 diagnosis. These
deaths were concentrated in institutions from less developed
regions, implying that when comprehensive ICU services are
not fully available, COVID-19 in pregnancy can be lethal. Reassuringly, we also found that asymptomatic women with
COVID-19 diagnosis had similar outcomes to women without
COVID-19 diagnosis, except for preeclampsia.
Importantly, women with COVID-19 diagnosis, already at
high risk of preeclampsia and COVID-19 because of preexisting overweight, diabetes, hypertension, and cardiac and
chronic respiratory diseases,28 had almost 4 times greater risk
of developing preeclampsia/eclampsia, which could reflect the
known association with these comorbidities and/or the acute
kidney damage that can occur in patients with COVID-19.29
Our data support reports of an association between
COVID-19 and higher rates of preeclampsia/eclampsia/
HELLP syndrome,19,30 but it is still uncertain whether COVID-19
manifests in pregnancy with a preeclampsialike syndrome or
infection with SARS-CoV-2 results in an increased risk for preeclampsia. Uncertainty persists because the placentas of
women with COVID-19, compared with controls, show vascular changes consistent with preeclampsia,31 but the state of systemic inflammation and hypercoagulability found in nonpregnant patients with severe illness and COVID-19 is also a feature
of preeclampsia.32

NICU stay ≥7 d

b

SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.

c

SPMMI includes any of the morbidities listed in the SNMI, intrauterine or
neonatal death, or NICU stay ⱖ7 days.

It is known that in nonpregnant patients, distinct subtypes may be predictive of clinical outcomes.33 We found
the presence of any COVID-19 symptoms was associated
with increased morbidity and mortality. Specifically, severe
pregnancy and neonatal complication rates were highest in
women if fever and shortness of breath were present,
reflecting systemic disease; their presence for 1 to 4 days
was associated with severe maternal and neonatal complications. This observation should influence clinical care and
referral strategies.
The risks of severe neonatal complications, including
NICU stay for 7 days or longer, as well as the summary index
of severe neonatal morbidity and its individual components, were also substantially higher in the group of women
with COVID-19 diagnosis. The increased neonatal risk
remained after adjusting for previous preterm birth and preterm birth in the index pregnancy; thus, a direct effect on
the newborn from COVID-19 is likely.
Overall, our results were consistent across morbidities and
mostly at an RR near or greater than 2 for maternal and neonatal outcomes, with narrow CIs excluding unity, and above 3
to 4 in several estimates. Sensitivity and stratified analyses confirmed the observed results. They are probably conservative
because overall, 41% of women with COVID-19 diagnosis were
asymptomatic, a subgroup with a low risk of complications.
Hence, higher morbidity and mortality risk should be expected for the general pregnant population, especially in lowto middle-income countries.
We found 12.1% of neonates born to test-positive women
also tested positive, a higher figure than in a recent systematic review.34 We speculate whether contamination at the time
of cesarean delivery was responsible because the rate in this
mother/neonate positive subgroup was 72.2%. Reassuringly,
as SARS-CoV-2 has not been isolated from breast milk,35 breastfeeding was not associated with any increase in the rate of testpositive neonates.
Our results mostly reflect COVID-19 diagnosed in the third
trimester. Thus, women with COVID-19 diagnosis or whose
pregnancy ended earlier in pregnancy are underrepresented
either because our study was exclusively hospital based or earlier infection may manifest with mild symptoms, which are
either ignored or managed in primary care. Alternatively, most
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women might have avoided the hospital until late in pregnancy or when in labor. Clearly, the effect of COVID-19 early
in pregnancy needs urgently to be studied.

Limitations
Our study has expected limitations. Ideally, we would have collected data prospectively from all pregnancies in the participating institutions, but this was impractical because of their large
number of deliveries. There was a small risk of selection bias associated with the reference group of women without COVID-19
diagnosis, despite all efforts to ensure they represented an unbiased sample of the general noninfected pregnant population.
The selection of cases with COVID-19 diagnosis was affected by
whether routine testing was conducted, awareness of COVID-19
symptoms particularly early in the pandemic, and the availability of test kits. Where universal testing in pregnancy has been
introduced, real-time polymerase chain reaction positive rates
are 0.5% to 14% in asymptomatic women.36,37 Hence, this group
of women without COVID-19 diagnosis may have included small
numbers of asymptomatic infected women (a crossover effect
when women without COVID-19 diagnosis were enrolled ante-
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natally), which would result in more conservative estimates by
reducing the differences between groups. Finally, we acknowledge a risk of reporting bias relating to maternal and neonatal
morbidity because women with COVID-19 diagnosis and their
newborns may have been more carefully evaluated, tested, and
have more events reported than in the sample of women without COVID-19 diagnosis. However, we are reassured that the results reflect a true increased risk because of our careful data
monitoring and use of severe morbidity markers.

Conclusions
In summary, in this study, COVID-19 infection during pregnancy was associated with substantial risk of morbidity and
mortality in postpartum parents and their infants worldwide,
compared with their not-infected pregnant counterparts, especially if the these individuals were symptomatic or have comorbidities. There is an urgent need to follow up with these
parents and infants because of possible long-term health effects, including long-term COVID-19.

Hôpitaux Universitaires de Strasbourg, Strasbourg,
France (Deruelle); Division of Maternal-Fetal
Medicine, Brigham and Women’s Hospital, Harvard
Medical School, Boston, Massachusetts (Easter);
Division of Critical Care Medicine, Brigham and
Women’s Hospital, Harvard Medical School, Boston,
Massachusetts (Easter); Hôpital Universitaire
Necker-Enfants Malades, AP-HP, Université de
Paris, Paris, France (Sichitiu); Division Neonatología,
Hospital Materno Infantil Ramón Sarda, Buenos
Aires Argentina (Soto Conti, Nieto); Department of
Obstetrics and Gynecology, Medical Faculty,
Universitas Airlangga, Surabaya, Indonesia
(Ernawati); Soetomo General Academic Hospital,
Surabaya, Indonesia (Ernawati); Tufts Medical
Center, Boston, Massachusetts (Mhatre); Ann and
Robert H. Lurie Children’s Hospital of Chicago,
Northwestern Feinberg School of Medicine,
Chicago, Illinois (Teji); St George’s University
Hospitals NHS Foundation Trust, London, United
Kingdom (Liu, Papageorghiou); Servicio de
Neonatologia del Departamento Materno Infantil
del Hospital Universitario Austral, Pilar, Provincia de
Buenos Aires, Argentina (Capelli); S.C. Obstetrics
2U, Sant’Anna Hospital, AOU Città della Salute e
della scienza di Torino, Turin, Italy (Oberto); Fetal
Medicine Unit, University College London Hospitals
NHS Foundation Trust, London, United Kingdom
(Salazar); Department of Obstetrics and
Gynecology, University of Washington, Seattle
(Gravett); Department of Global Health, University
of Washington, Seattle (Gravett); Obstetrics and
Gynaecology Department, IRCCS San Raffaele
Hospital and University, Milan, Italy (Cavoretto); Fr.
Thomas Alan Rooney Memorial Hospital,
Asankragwa, Ghana (Nachinab); Africa Center of
Excellence for Population Health and Policy, Bayero
University Kano, Kano, Nigeria (Galadanci); Aminu
Kano Teaching Hospital, Kano, Nigeria (Galadanci);
Aragon Institute of Health Research, Obstetrics
Department, Hospital Clínico Universitario Lozano
Blesa Zaragoza, Zaragoza, Spain (Oros); College of
Medicine, University of Ibadan, Ibadan, Nigeria
(Ayede, John-Akinola); University College Hospital,
Ibadan, Nigeria (Ayede, John-Akinola); Department

JAMA Pediatrics Published online April 22, 2021 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Aga Khan University User on 05/31/2021

of Obstetrics and Gynecology, Bordeaux University
Hospital, Bordeaux, France (Sentilhes); Department
of Obstetrics and Gynaecology, Faculty of Clinical
Sciences, College of Medical Sciences, Gombe State
University, Gombe, Nigeria (Bako); Hospital de
Moron, Moron, Provincia de Buenos Aires,
Argentina (Savorani); Laboratory of Dietetics and
Clinical Nutrition, Department of Public Health,
Experimental and Forensic Medicine, University of
Pavia, Pavia, Italy (Cena); Clinical Nutrition and
Dietetics Service, Unit of Internal Medicine and
Endocrinology, ICS Maugeri IRCCS, University of
Pavia, Pavia, Italy (Cena); Hospital Regional Lic.
Adolfo López Mateos ISSSTE, Mexico City, Mexico
(García-May); University of Calabar Teaching
Hospital, Calabar, Nigeria (Etuk); Maternal and Child
Department, Hospital Nacional Profesor Alejandro
Posadas, Buenos Aires, Argentina (Casale); Tropical
Medicine and Infectious Diseases Department,
Tanta University, Tanta, Egypt (Abd-Elsalam);
Department of Obstetrics and Gynecology, Keio
University School of Medicine, Tokyo, Japan
(Ikenoue); Department of Obstetrics and
Gynaecology, Abubakar Tafawa Balewa University
Teaching Hospital, Bauchi, Nigeria (Aminu);
Sanatorio Otamendi, Ciudad de Buenos Aires,
Argentina (Vecciarelli); Universidad de Buenos
Aires, Buenos Aires, Argentina (Duro); Universidad
de Moron, Moron, Argentina (Duro); Department of
Obstetrics and Gynaecology, Muhammad Abdullahi
Wase Teaching Hospital, Kano State, Nigeria
(Usman); Center for Global Child Health, Hospital
for Sick Children, Toronto, Ontario, Canada
(Bhutta); Women and Health Initiative, Global
Health and Population Department, Harvard T.H.
Chan School of Public Health, Boston,
Massachusetts (Langer).
Author Contributions: Drs Villar and
Papageorghiou had full access to all of the data in
the study and take responsibility for the integrity of
the data and the accuracy of the data analysis. Drs
Kennedy and Papageorghiou contributed equally.
Concept and design: Villar, Thiruvengadam, Arturo
Cardona-Perez, Ayede, Bako, Duro, Langer,

jamapediatrics.com

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection

Kennedy, Papageorghiou.
Acquisition, analysis, or interpretation of data: Villar,
Ariff, Gunier, Thiruvengadam, Rauch, Kholin,
Roggero, Prefumo, Silva do Vale, Maiz, Cetin,
Savasi, Deruelle, Easter, Sichitiu, Soto Conti,
Ernawati, Mhatre, Singh Teji, Liu, Capelli, Oberto,
Salazar, Gravett, Cavoretto, Bizor Nachinab,
Galadanci, Oros, Ayede, Sentilhes, Bako, Savorani,
Cena, Garcia-May, Etuk, Casale, Abd-Elsalam,
Ikenoue, Baffah Aminu, Vecchiarelli, Usman,
John-Akinola, Nieto, Ferrazzi, Bhutta,
Papageorghiou.
Drafting of the manuscript: Villar, Gunier,
Thiruvengadam, Rauch, Prefumo, Maiz, Singh Teji,
Liu, Etuk, Kennedy, Papageorghiou.
Critical revision of the manuscript for important
intellectual content: Villar, Ariff, Thiruvengadam,
Kholin, Roggero, Prefumo, Silva do Vale, Arturo
Cardona-Perez, Cetin, Savasi, Deruelle, Easter,
Sichitiu, Soto Conti, Ernawati, Mhatre, Singh Teji,
Capelli, Oberto, Salazar, Gravett, Cavoretto, Bizor
Nachinab, Galadanci, Oros, Ayede, Sentilhes, Bako,
Savorani, Cena, Garcia-May, Casale, Abd-Elsalam,
Ikenoue, Baffah Aminu, Vecchiarelli, Duro, Usman,
John-Akinola, Nieto, Ferrazzi, Bhutta, Langer,
Kennedy, Papageorghiou.
Statistical analysis: Villar, Gunier, Rauch,
Papageorghiou.
Obtained funding: Villar, Papageorghiou.
Administrative, technical, or material support: Villar,
Ariff, Thiruvengadam, Silva do Vale, Arturo
Cardona-Perez, Savasi, Easter, Sichitiu, Ernawati,
Singh Teji, Liu, Galadanci, Oros, Ayede, Bako,
Savorani, Garcia-May, Etuk, Baffah Aminu,
John-Akinola, Papageorghiou.
Supervision: Villar, Thiruvengadam, Kholin,
Roggero, Cetin, Savasi, Ayede, Cena, Etuk, Usman,
Ferrazzi, Langer, Papageorghiou.
Conflict of Interest Disclosures: Dr Gunier
reported grants from Oxford University during the
conduct of the study. Dr Sentilhes reported
personal, lecture, and consulting fees from Ferring
Pharmaceutical and personal and lecture fees from
Bayer outside the submitted work. Dr
Papageorghiou reported grants from National
Institute for Health Research Biomedical Research
Centre and other support from Intelligent
Ultrasound as director outside the submitted work.
No other disclosures were reported.
Funding/Support: The study was supported by the
COVID-19 Research Response Fund from the
University of Oxford (reference 0009083).
Dr Papageorghiou is supported by the Oxford
Partnership Comprehensive Biomedical Research
Centre with funding from the National Institute for
Health Research Biomedical Research Centre
Biomedical Research Centre funding scheme.
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of the manuscript; and decision to submit
the manuscript for publication.
Disclaimer: The views expressed herein are those
of the authors and not necessarily those of the UK
National Health System, the US National Institute
for Health Research Department of Health, or any
of the other funders.
Additional Contributions: We are grateful to the
following colleagues for their contributions to the
study: Josephine Agyeman-Duah, MSc (Nuffield
Department of Women’s & Reproductive Health,

University of Oxford, Oxford, UK), study
coordinator, Nkawkaw, Ghana; Eric Baafi, MD (Holy
Family Hospital, Nkawkaw, Ghana), data collection,
Ghana; Anne Caroline Benski, MD (Hôpitaux
Universitaires de Genève, Département de la
Femme, de l’Enfant et de l'Adolescent, Geneva,
Switzerland), data collection, Geneva, Switzerland;
Rachel Craik, BSc (Nuffield Department of Women’s
& Reproductive Health, University of Oxford,
Oxford, UK), study coordinator (overall study);
Sonia Deantoni, MD (Nuffield Department of
Women’s & Reproductive Health, University of
Oxford, Oxford, UK; Oxford Maternal and Perinatal
Health Institute, Green Templeton College,
University of Oxford, Oxford, UK; Neonatal Care
Unit, Department of Public Health and Pediatrics,
School of Medicine, University of Turin, Italy), data
collection, Oxford, UK, and data input (multiple
sites); Ken Takahashi, PhD (Department of
Obstetrics and Gynecology, The Jikei University
School of Medicine, Tokyo, Japan), data collection,
Jikei, Japan; Gabriela Tavchioska, MSc (Department
of Pediatrics, General Hospital Borka Taleski, Prilep,
Republic of North Macedonia), data collection,
Prilep, Republic of North Macedonia; Jim G.
Thornton, MD (Division of Child Health, Obstetrics
and Gynaecology, University of Nottingham,
Nottingham, UK), literature reviews and study
advisor; Albertina Rego, PhD (Departamento de
Pediatria, Faculdade Universidade Federal de Minas
Gerais, Belo Horizonte, Brazil), study coordinator,
Brazil; and Adele Winsey, PhD (Nuffield
Department of Women’s & Reproductive Health,
University of Oxford, Oxford, UK), study
coordinator (overall study). Dr Winsey and Ms Craik
were supported by the COVID-19 Research
Response Fund from the University of Oxford.
Other contributors did not receive any
compensation (eAppendix 1 in the Supplement).
We also thank all the contributing institutions and
local researchers involved in the study. eAppendix 2
in the Supplement contains their details as well as
details of the study committees.
REFERENCES
1. Wu Y, Zhang C, Liu H, et al. Perinatal depressive
and anxiety symptoms of pregnant women during
the coronavirus disease 2019 outbreak in China. Am
J Obstet Gynecol. 2020;223(2):240.e1-240.e9.
doi:10.1016/j.ajog.2020.05.009
2. Davenport MH, Meyer S, Meah VL, Strynadka
MC, Khurana R. Moms are not OK: COVID-19 and
maternal mental health. Front Glob Womens Health.
Published online June 19, 2020. doi:10.3389/fgwh.
2020.00001
3. Yap M, Debenham L, Kew T, et al; PregCOV-19
Consortium. Clinical manifestations, prevalence,
risk factors, outcomes, transmission, diagnosis and
treatment of COVID-19 in pregnancy and
postpartum: a living systematic review protocol.
BMJ Open. 2020;10(12):e041868. doi:10.1136/
bmjopen-2020-041868
4. Campbell KH, Tornatore JM, Lawrence KE, et al.
Prevalence of SARS-CoV-2 among patients
admitted for childbirth in southern Connecticut.
JAMA. 2020;323(24):2520-2522. doi:10.1001/jama.
2020.8904
5. Knight M, Bunch K, Vousden N, et al; UK
Obstetric Surveillance System SARS-CoV-2 Infection
in Pregnancy Collaborative Group. Characteristics
and outcomes of pregnant women admitted to
hospital with confirmed SARS-CoV-2 infection in

jamapediatrics.com

Downloaded From: https://jamanetwork.com/ by a Aga Khan University User on 05/31/2021

Original Investigation Research

UK: national population based cohort study. BMJ.
2020;369:m2107. doi:10.1136/bmj.m2107
6. Li N, Han L, Peng M, et al. Maternal and neonatal
outcomes of pregnant women with coronavirus
disease 2019 (COVID-19) pneumonia: a case-control
study. Clin Infect Dis. 2020;71(16):2035-2041.
doi:10.1093/cid/ciaa352
7. Liao J, He X, Gong Q, Yang L, Zhou C, Li J.
Analysis of vaginal delivery outcomes among
pregnant women in Wuhan, China during the
COVID-19 pandemic. Int J Gynaecol Obstet. 2020;
150(1):53-57. doi:10.1002/ijgo.13188
8. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East
Respiratory Syndrome Coronavirus (MERS-CoV)
infection during pregnancy: report of two cases &
review of the literature. J Microbiol Immunol Infect.
2019;52(3):501-503. doi:10.1016/j.jmii.2018.04.005
9. World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194. doi:10.
1001/jama.2013.281053
10. The Global Health Network. INTERCOVID.
Accessed April 5, 2021. https://intergrowth21.tghn.
org/intercovid/
11. Shi H, Han X, Jiang N, et al. Radiological findings
from 81 patients with COVID-19 pneumonia in
Wuhan, China: a descriptive study. Lancet Infect Dis.
2020;20(4):425-434. doi:10.1016/S1473-3099(20)
30086-4
12. Bauchner H, Golub RM, Zylke J. Editorial
concern-possible reporting of the same patients
with COVID-19 in different reports. JAMA. 2020;
323(13):1256. doi:10.1001/jama.2020.3980
13. Kayem G, Lecarpentier E, Deruelle P, et al. A
snapshot of the Covid-19 pandemic among
pregnant women in France. J Gynecol Obstet Hum
Reprod. 2020;49(7):101826. doi:10.1016/j.jogoh.
2020.101826
14. Sentilhes L, De Marcillac F, Jouffrieau C, et al.
Coronavirus disease 2019 in pregnancy was
associated with maternal morbidity and preterm
birth. Am J Obstet Gynecol. 2020;223(6):914.e1914.e15. doi:10.1016/j.ajog.2020.06.022
15. Maraschini A, Corsi E, Salvatore MA, Donati S, It
OSSC-WG; ItOSS COVID-19 Working Group.
Coronavirus and birth in Italy: results of a national
population-based cohort study. Ann Ist Super Sanita.
2020;56(3):378-389.
16. Ferrazzi E, Beretta P, Bianchi S, et al.
SARS-CoV-2 infection testing at delivery: a clinical
and epidemiological priority. J Matern Fetal
Neonatal Med. 2020;1-3. doi:10.1080/14767058.
2020.1788532
17. Collaborative CO; COVIDSurg Collaborative.
Mortality and pulmonary complications in patients
undergoing surgery with perioperative SARS-CoV-2
infection: an international cohort study. Lancet.
2020;396(10243):27-38. doi:10.1016/S0140-6736
(20)31182-X
18. Ochiai D, Kasuga Y, Iida M, Ikenoue S, Tanaka M.
Universal screening for SARS-CoV-2 in
asymptomatic obstetric patients in Tokyo, Japan.
Int J Gynaecol Obstet. 2020;150(2):268-269.
doi:10.1002/ijgo.13252
19. Mendoza M, Garcia-Ruiz I, Maiz N, et al.
Pre-eclampsia-like syndrome induced by severe
COVID-19: a prospective observational study. BJOG.
2020;127(11):1374-1380. doi:10.1111/1471-0528.16339

(Reprinted) JAMA Pediatrics Published online April 22, 2021

E9

Research Original Investigation

20. Lokken EM, Walker CL, Delaney S, et al. Clinical
characteristics of 46 pregnant women with a severe
acute respiratory syndrome coronavirus 2 infection
in Washington State. Am J Obstet Gynecol. 2020;
223(6):911.e1-911.e14. doi:10.1016/j.ajog.2020.05.031
21. Onwuzurike C, Diouf K, Meadows AR, Nour NM.
Racial and ethnic disparities in severity of COVID-19
disease in pregnancy in the United States. Int J
Gynaecol Obstet. 2020;151(2):293-295. doi:10.
1002/ijgo.13333
22. Goldfarb IT, Diouf K, Barth WH, et al. Universal
SARS-CoV-2 testing on admission to the labor and
delivery unit: Low prevalence among asymptomatic
obstetric patients. Infect Control Hosp Epidemiol.
2020;41(9):1095-1096. doi:10.1017/ice.2020.255
23. Docherty AB, Harrison EM, Green CA, et al;
ISARIC4C investigators. Features of 20 133 UK
patients in hospital with covid-19 using the ISARIC
WHO Clinical Characterisation Protocol:
prospective observational cohort study. BMJ. 2020;
369:m1985. doi:10.1136/bmj.m1985
24. Villar J, Valladares E, Wojdyla D, et al; WHO
2005 global survey on maternal and perinatal
health research group. Caesarean delivery rates and
pregnancy outcomes: the 2005 WHO global survey
on maternal and perinatal health in Latin America.
Lancet. 2006;367(9525):1819-1829. doi:10.1016/
S0140-6736(06)68704-7
25. Papageorghiou AT, Kennedy SH, Salomon LJ,
et al; International Fetal and Newborn Growth
Consortium for the 21st Century (INTERGROWTH21st). International standards for early fetal size and
pregnancy dating based on ultrasound

E10

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection

measurement of crown-rump length in the first
trimester of pregnancy. Ultrasound Obstet Gynecol.
2014;44(6):641-648. doi:10.1002/uog.13448
26. Villar J, Cheikh Ismail L, Victora CG, et al;
International Fetal and Newborn Growth
Consortium for the 21st Century (INTERGROWTH21st). International standards for newborn weight,
length, and head circumference by gestational age
and sex: the Newborn Cross-Sectional Study of the
INTERGROWTH-21st Project. Lancet. 2014;384
(9946):857-868. doi:10.1016/S0140-6736(14)
60932-6
27. Ohuma EO, Hoch L, Cosgrove C, et al;
International Fetal and Newborn Growth
Consortium for the 21st Century. Managing data for
the international, multicentre INTERGROWTH-21st
Project. BJOG. 2013;120(suppl 2):64-70, v. doi:10.
1111/1471-0528.12080
28. Savasi VM, Parisi F, Patanè L, et al. Clinical
findings and disease severity in hospitalized
pregnant women with coronavirus disease 2019
(COVID-19). Obstet Gynecol. 2020;136(2):252-258.
doi:10.1097/AOG.0000000000003979

31. Shanes ED, Mithal LB, Otero S, Azad HA, Miller
ES, Goldstein JA. Placental pathology in COVID-19.
Am J Clin Pathol. 2020;154(1):23-32. doi:10.1093/
ajcp/aqaa089
32. Narang K, Enninga EAL, Gunaratne MDSK, et al.
SARS-CoV-2 infection and COVID-19 during
pregnancy: a multidisciplinary review. Mayo Clin Proc.
2020;95(8):1750-1765. doi:10.1016/j.mayocp.2020.
05.011
33. Sudre CH, Lee KA, Ni Lochlainn M, et al.
Symptom clusters in Covid19: a potential clinical
prediction tool from the COVID Symptom study
app. medRxiv. Preprint posted online June 16, 2020.
doi:10.1101/2020.06.12.20129056
34. Walker KF, O’Donoghue K, Grace N, et al.
Maternal transmission of SARS-COV-2 to the
neonate, and possible routes for such transmission:
a systematic review and critical analysis. BJOG.
2020;127(11):1324-1336. doi:10.1111/1471-0528.16362
35. Chambers C, Krogstad P, Bertrand K, et al.
Evaluation for SARS-CoV-2 in breast milk from 18
infected women. JAMA. 2020;324(13):1347-1348.
doi:10.1001/jama.2020.15580

29. Ronco C, Reis T, Husain-Syed F. Management of
acute kidney injury in patients with COVID-19.
Lancet Respir Med. 2020;8(7):738-742. doi:10.
1016/S2213-2600(20)30229-0

36. Sutton D, Fuchs K, D’Alton M, Goffman D.
Universal screening for SARS-CoV-2 in women
admitted for delivery. N Engl J Med. 2020;382(22):
2163-2164. doi:10.1056/NEJMc2009316

30. Di Mascio D, Khalil A, Saccone G, et al.
Outcome of coronavirus spectrum infections
(SARS, MERS, COVID-19) during pregnancy:
a systematic review and meta-analysis. Am J Obstet
Gynecol MFM. 2020;2(2):100107. doi:10.1016/j.
ajogmf.2020.100107

37. Fassett MJ, Lurvey LD, Yasumura L, et al.
Universal SARS-Cov-2 screening in women
admitted for delivery in a large managed care
organization. Am J Perinatol. 2020;37(11):1110-1114.
doi:10.1055/s-0040-1714060

JAMA Pediatrics Published online April 22, 2021 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Aga Khan University User on 05/31/2021

jamapediatrics.com

